Key facts
- This page summarizes Jeffrey Lawrence Schwartz's Form 4 filing for RAPID MICRO BIOSYSTEMS, INC. (RPID).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 May 2024, 16:59.
Jeffrey Lawrence Schwartz - 23 May 2024 Form 4 Insider Report for RAPID MICRO BIOSYSTEMS, INC. (RPID)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- RPID
- Reported as of
- 23 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 May 2024, 16:59:40 UTC
- Prior SEC filing
- 25 May 2023
- Next SEC filing
- 06 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Schwartz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Lawrence Schwartz filed Form 4 for RAPID MICRO BIOSYSTEMS, INC. (RPID) on 28 May 2024.
Change
- Previous filing in this sequence was filed on 25 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RPID
transaction
Class A Common Stock
Award
- Transaction value
- $0
- Shares
- +14,300
- Change %
- Price
- $0.000000
- Shares after
- 14,300
- Date
- 23 May 2024
- Ownership
- Direct
- Footnotes
- F1
RPID
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,434,560
- Date
- 23 May 2024
- Ownership
- See footnotes
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RPID
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +28,650
- Change %
- Price
- $0.000000
- Shares after
- 28,650
- Date
- 23 May 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 28,650
- Exercise price
- $0.8200
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date.
Footnote F2
The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date.
Footnote F3
Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS Fund I") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS Fund I, the "Bain Capital Life Sciences Entities").
Footnote F4
Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS Fund I and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Mr. Schwartz is a Partner of BCLSI. By virtue of the relationships described in this footnote, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.